August 28, 2012
JCR Pharmaceuticals announced on August 24 that it obtained on the same day approval for an additional indication of small-for-gestational-age (SGA) dwarfism without epiphyseal closing for the recombinant human growth hormone Growject (somatropin), the company’s mainstay product. Growject is approved...read more